Veenendaal

Researchers are evaluating the B-COMPASS, a disease-agnostic computational model designed to predict patient adherence to treatment and identify their support needs across various health conditions. The study aims to validate the B-COMPASS's accuracy, validity, reliability, and effectiveness in improving treatment adherence and healthcare cost-effectiveness. This model is being tested in real-life settings, involving patients with cardiovascular, endocrine, immunology, neurology, oncology, and rare diseases recruited from multiple European countries. Participants will either receive standard care or enhanced engagement through the B-COMPASS intervention. In the intervention group, healthcare providers receive educational materials tailored to each patient's B-COMPASS profile, which guides personalized patient support. Engagement with patients occurs either in person or by phone, depending on each patient's schedule. The study includes iterative refinements of the model based on validation results from six therapeutic areas. During the study, participants will undergo two main data collection points ranging from 2 weeks to 6 months apart to assess the B-COMPASS's predictive accuracy and stability over time. Researchers will evaluate outcomes such as the model's adherence prediction accuracy, validity of patient groupings, identification of support needs, and reliability. The study also measures patient and healthcare provider perceptions of the model and its impact on healthcare utilization costs, aiming to improve patient experience and adherence through tailored support.

This research evaluates the effectiveness of the RISE blended behavior change intervention in people who have experienced their first stroke. The study aims to prevent major adverse cardiovascular events such as recurrent stroke, transient ischemic attacks, acute coronary events, and cardiovascular death over a one-year follow-up period compared to standard care. It also investigates the intervention's impact on reducing sedentary behavior after hospital discharge in community-dwelling stroke survivors with sedentary movement patterns. Approximately 950 to 1000 participants are expected to be enrolled to account for loss to follow-up. Participants are randomly assigned to an experimental group receiving the 15-week RISE intervention alongside usual care or to a control group receiving only usual care. The RISE intervention involves coaching by a primary care physiotherapist who supports participants in balancing their 24-hour activity pattern, focusing on reducing and interrupting sedentary time to increase physical activity. This coaching includes the use of an activity monitor, a smartphone application with real-time feedback and e-learning modules, and a dashboard for the physiotherapist. Support from someone in the participant's social network is also included. Control group participants receive hospital-specific standard care. Participants will undergo assessments at baseline, immediately post-treatment (four months), and at six, nine, and twelve months after randomization. These assessments include wearing activity monitors, completing questionnaires, and performing physical tests, all of which are non-invasive and conducted either online or at home. Researchers monitor the occurrence of major adverse cardiovascular events as the primary outcome. The study's burden and risks are considered low, with physiotherapist visits conducted at home or online, and participants are physically capable of completing the required activities.